Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes mellitus: A pharmacoeconomic model of the CARDS study;Análisis coste-efectividad del uso de atorvastatina en pacientes diabéticos de tipo 2: Modelo farmacoeconómico del estudio CARDS

Anales de Medicina Interna

Volumn 23, Issue 5, 2006, Pages 213-219

  Fernandez De Bobadilla J ^a   Lopez De Sa E ^b   Alonso Troncoso, I ^c   Moreno Gomez R ^d   Rubio Terrés, Carlos ^e   Soto Alvarez J ^a  

^a PFIZER INC   (United States)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL MONTECELO   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HERO Consulting   (Spain)

Author keywords

Atorvastatin; Cost effectiveness; Diabetes mellitus; Primary prevention

Indexed keywords

ATORVASTATIN; PLACEBO; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE MODEL; HUMAN; LIFE EXPECTANCY; MEDICAL RESEARCH; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; ADULT; AGED; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES;

EID: 33947591975     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Arroyo J, Badía X, Calle H. Tratamiento de los pacientes con diabetes mellitus tipo 2 en atención primaria en España. Med Clin (Barc) 2005; 125: 166-72.
2. Goday A, Gabriel R, Ascaso JF, et al. Despistaje y seguimiento de la insulina resistencia en España: Estudio DESIRE. Avances en Diabetología, 2004. Sociedad Española de Diabetes. Vol.20.Supl.1. Mayo 2004.
3. Goday A, Serrano Ríos M. Epidemiología de la Diabetes Mellitus en España. Revisión crítica y nuevas perspectivas. Med Clin (Barc) 1994; 102: 306-315.
4. Gimeno Orna JA, Boned Juliani B, Lou Arnal L. M, et al. Mortalidad en una cohorte de pacientes con diabetes tipo 2 del Área de Alcañiz. An Med Interna (Madrid) 2002; 19: 14-18.
5. Cerveny JD, Leder RD, Weart CW Issues surrounding tight glycemic control in people with type 2 diabetes mellitus.Ann Pharmacother 1998; 32: 896-905
6. Calvo Romero, J. Ma and Lima Rodríguez, E. Ma Objetivos y estrategia terapéutica en la diabetes mellitus tipo 2 . An Med Interna (Madrid) 2001; 18: 41-48.
7. Pérez García, R., Rodríguez Benítez, P., Dall'Anesse, C. et al. Preocupante incremento de la diabetes como causa de insuficiencia renal terminal: Evaluación del tratamiento sustitutivo. An Med Interna (Madrid) 2001; 18: 7-14.
8. Williams R, Van Gaal L, Lucioni C, CODE-2 Advisory Board. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002; 45: S13-S17.
9. Pascual JM.,González, C, Juan García, S. de. Impacto de la diabetes mellitus en los costes de hospitalización. Med Clin (Barc), 1996; 107.
10. National Diabetes Data Group. Diabetes in America. National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases. NIH Publication No. 95-1468. Bethesda: NIH, 1995.
11. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
12. Colhoun HM, Betteridge JD, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled. Lancet 2004; 364: 685-96.
13. Rubio-Terrés C, Sacristán JA, Badía X, Cobo E, García Alonso F, por el Grupo ECOMED. Métodos utilizados para realizar evaluaciones económicas de intervenciones sanitarias. Med Clin (Barc) 2004; 122: 578-83.
14. Manuel DG, Schultz SE. Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada, 1996-1997. Diabetes Care 2004; 27: 407-14.
15. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR; UK Prospective Diabetes Study (UKDPS) Group.A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004; 47: 1747-59. Epub 2004 Oct 27.
16. Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value in Health 2004; 7: 627-35.
17. Rovira J, Antoñanzas F. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics 1995; 8: 245-52.
18. Canadian Coordinating Office for Health Technology Assessment. Guideline for economic evaluation of pharmaceuticals: Canada. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997.
19. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices - modeling studies. Value in Health 2003; 6: 9-17.
20. Base de datos de medicamentos. Consejo General de Colegios Oficiales de Farmacéuticos. Disponible en URL: http://www.portalfarma.com/home.nsf (consulta: junio, 2005).
21. Gisbert R, Brosa M. Base de datos de costes sanitarios. Versión 2.2. Barcelona: Soikos, 2005.
22. Tappenden P, Chilcott JB, Eggington S, Oakley J, McCabe C. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-a and glatiramer acetate for multiple sclerosis. Health Technol Assess 2004; 8: 1-92.
23. Ortún Rubio V. Clínica y gestión. Med Clin (Barc) 1995; 104: 298-300.
24. Del Llano J, Oliva J. Medicina coste-efectiva y medicina basada en la evidencia: su impacto en el proceso de decisiones clínicas. Med Clin (Barc) 2000; 114 (Supl. 3): 34-41.
25. Soto Álvarez, J. Valor terapéutico añadido de los medicamentos: ¿qué es, cómo se evalúa y cuál debería ser su papel en política farmacéutica? An Med Interna (Madrid) 2005; 22: 39-42.
26. Lee JT, Sánchez LA. Interpretation of cost-effectiveness and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm 1991; 48: 2622-7.
27. Laupacis A, Fenny D, Detsky A, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-81.
28. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit 2002; 16: 334-43.